Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease by Padam, P. et al.
Reduced healthcare utilization following successful hepatitis C
virus treatment in HIV-co-infected patients with mild liver
disease
P. Padam,1 S. Clark,1 W. Irving,2 R. Gellissen,3 E. Thomson,4 J. Main5 and G. S. Cooke1
1Division of Infectious Diseases, Imperial College London, London, UK; 2NIHR Biomedical Research Unit in Gastroenterology and the Liver,
University of Nottingham, Nottingham, UK; 3Department of Hepatology, Imperial College NHS Trust, London, UK; 4MRC Centre for Virus
Research, University of Glasgow, Glasgow, UK; and 5Department of Medicine, Imperial College London, London, UK
Received March 2015; accepted for publication August 2015
SUMMARY. New direct-acting antivirals (DAA) for hepatitis
C virus (HCV) infection have achieved high cure rates in
many patient groups previously considered difficult-to-
treat, including those HIV/HCV co-infected. The high price
of these medications is likely to limit access to treatment,
at least in the short term. Early treatment priority is likely
to be given to those with advanced disease, but a more
detailed understanding of the potential benefits in treating
those with mild disease is needed. We hypothesized that
successful HCV treatment within a co-infected population
with mild liver disease would lead to a reduction in the
use and costs of healthcare services in the 5 years follow-
ing treatment completion. We performed a retrospective
cohort study of HIV/HCV-co-infected patients without evi-
dence of fibrosis/cirrhosis who received a course of HCV
therapy between 2004 and 2013. Detailed analysis of
healthcare utilization up to 5 years following treatment for
each patient using clinical and electronic records was used
to estimate healthcare costs. Sixty-three patients were
investigated, of whom 48 of 63 (76.2%) achieved sus-
tained virological response 12 weeks following completion
of therapy (SVR12). Individuals achieving SVR12 incurred
lower health utilization costs (£5000 per-patient) compared
to (£10 775 per-patient) non-SVR patients in the 5 years
after treatment. Healthcare utilization rates and costs in
the immediate 5 years following treatment were signifi-
cantly higher in co-infected patients with mild disease that
failed to achieve SVR12. These data suggest additional
value to achieving cure beyond the prevention of complica-
tions of disease.
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INTRODUCTION
Hepatitis C virus (HCV) is estimated to have infected over
170 million people worldwide, accounting for 3% of the
global population [1]. Co-infection with HIV and HCV is
common due to shared routes of transmission with the
prevalence of co-infection ranging from 9% to 30% in dif-
ferent settings [2–5]. Since the introduction of highly
active antiretroviral therapies (HAART) and the reduction
in mortality from malignancy and opportunistic infection,
hepatic disorders have become a leading cause of death for
patients with HIV in developed nations [6–8], with HCV
playing a major role. HIV-infected individuals with HCV
experience more rapidly progressive fibrosis and an
increased risk of cirrhosis and hepatocellular carcinoma,
occurring in 25% and 1.6% of co-infected individuals over
their lifetime, respectively [9, 10].New direct-acting antivi-
rals (DAAs) against HCV have the potential to cure many
HCV/HIV-co-infected patients who have not tolerated or
have failed previous treatments. However, widespread
access to these treatments is currently beyond existing
health budgets [11] in most economies, and their initial
use is likely to be limited to patients with significant fibro-
sis or cirrhosis [12]. Strong justification of the cost benefit
of treatment in patients with mild disease will be required.
Several studies have reported higher usage of healthcare
services such as hospitalizations and emergency room visits
in co-infected individuals than amongst HIV-infected
patients [13–16]. There is some evidence that sustained
virological response (SVR) in HCV-monoinfected patients is
cost-saving [17]. In contrast to HCV-monoinfected patients,
HIV/HCV-co-infected patients remain in secondary care
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even when cured and the impact on healthcare utilization
has not been studied in this population.
We aimed to investigate whether HIV/HCV-co-infected
patients who were successfully treated for mild hepatitis C
had reduced usage of healthcare services and costs after
completion of successful treatment.
MATERIALS AND METHODS
Study population
Patients were eligible if they attended the study clinic
between 1 January 2004 and 1 March 2013. Patients
included for analysis required (i) confirmed positive HIV
antibody status, (ii) evidence of HCV infection, and for this
study, patients being positive for HCV RNA on more than
one occasion and (iii) to have received and completed at
least 3 months of treatment for HCV between 1 January
2004 and 1 March 2013. This would allow us to obtain
at least 1 year of follow-up for all patients by the date of
data collection, 1 March 2014. Patients were included
regardless of treatment type which included pegylated
interferon (PEG-IFN, both a-2b, Schering-Plough or a-2a,
Roche), ribavirin (RBV) and latterly protease inhibitors
(PI). Analysis was limited to patients without evidence of
significant fibrosis to avoid confounding by the fact that
patients with more advanced disease have greater health-
care costs and that those with most advanced disease
respond less well to therapy [18–20]. Patients we consid-
ered not to have significant fibrosis were those who had a
fibroscan result <9.6 kPa and/or a biopsy with ISHAK
stage score <2/6 in the 2 years prior to treatment. Individ-
uals who were currently on treatment were excluded from
the study. Treated patients were separated into two groups
based on outcome – those who attained SVR and those
that did not (non-SVR) as shown in Fig. 1. Patients were
recruited from a single centre where the majority of
patients are from West London, United Kingdom (UK).
Data on patient characteristics, clinical data and health-
care utilization were collected from clinical records supple-
mented by electronic records for investigations and
hospital attendance. Data collected independently by UK
collaborative HIV cohort (UKCHIC) [21] were used to
cross-reference information from hospital databases and
verify patient selection. UKCHIC is a collaboration that
routinely collects data on HIV-positive individuals who
have received care at any one of the associated centres in
the United Kingdom.
Baseline characteristics
Baseline patient information for the entire HIV/HCV-co-
infected cohort included the patient’s age, gender, race,
fibrosis/cirrhosis status, baseline laboratory data compris-
ing of CD4 count, HCV genotype, HCV and HIV viral loads,
fibroscan results and biopsies. Baseline analysis was then
repeated for SVR and non-SVR groups to allow comparison
between cohorts once individuals were identified. For both
groups, additional information on treatments given and
the precise dates of treatment completion were obtained
from patient records.
Healthcare utilization
Patients with mild liver disease who received a course of
PEG-IFN and RBV +/- protease inhibitors in line with the
Fig. 1 Selection of study cohort. aAs of
March 1 2014. HCV, hepatitis C virus;
HIV, human immunodeficiency virus;
SVR, sustained virological response.
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British HIV Association (BHIVA) guidelines were consid-
ered for medical service utilization analysis [22]. Forty-
eight patients who achieved SVR and fifteen non-SVR
patients were included. For each patient, annual resource
utilization data were recorded for up to 5 years post-treat-
ment with year 1 starting 12 weeks following treatment
cessation. Healthcare follow-up was conducted up until 1
March 2014. Outpatient attendances, clinic visits, hospital
admissions, nights spent at hospital, A&E visits, number of
bloods taken, HCV viral loads, number of USS and fibros-
cans were recorded. Clinic visits were denoted as consul-
tant-led encounters at the HIV study clinic. Outpatient
attendances included both planned and unplanned visits to
hospital outside of regular HIV clinic sessions. In the Uni-
ted Kingdom, a stable HIV patient routinely receives a fol-
low-up every 3–6 months as mentioned in the BHIVA
monitoring guidelines and will have a regular blood test at
least a week prior to each clinic visit. Individuals who are
not tolerating treatment or with additional complications
will need more frequent visits [23]. This study did not con-
sider pharmacy costs of HIV and other drugs received dur-
ing the follow-up period, which were assumed to be the
same in both SVR and non-SVR groups.
Statistical analysis and costs
We assessed differences in healthcare utilization by com-
parison of rates per-patient year of follow-up of each
healthcare service. We followed this by calculating total
utilization rates over the 5 years and compared total usage
per-patient year between SVR and non-SVR groups. Risk
ratios were then determined for non-SVR vs SVR patients.
Statistical significance was determined at P < 0.05 esti-
mated using two-sided Student’s t-tests. To fully assess the
benefits of attaining an SVR, we used mean costs as the
factor of comparison. Healthcare service costs were
obtained from the Department of Health using most recent
reference costs, 2012–2013 [24]. Unit costs were found to
be as follows: outpatient attendance including both visit
and average cost of outpatient procedure £240, consul-
tant-led HIV clinic visit £354, hospital admission £693,
night stays £1489 per night, A&E visit £115, bloods £27,
HCV viral load £75, diagnostic tests (fibroscans and ultra-
sound scans) each at £92. Total National Health Service
(NHS) expenditure for SVR and non-SVR patients during
the 5-year follow-up period was calculated using single
unit costs and utilization rates which were later compared.
RESULTS
SVR vs non-SVR characteristics
A total of 63 co-infected patients with mild liver disease
received and completed at least 3 months of antiviral ther-
apy between January 2004 and March 2013. Table 1
shows the comparison of baseline characteristics for SVR
and non-SVR groups. Overall, 48 of 63 patients (76%) had
successful treatment of which 28 patients (58%) had acute
infection. Both SVR and non-SVR groups comprised pre-
dominantly of males. The distribution of age varied
between groups where the majority (30/48, 62.5%) of
SVR patients were aged 45 or older, whereas (13/15)
86.6% of non-SVR patients were 44 or lower. A higher
proportion of genotype 1 patients (44/139, 32%) received
Table 1 Baseline characteristics of the SVR vs non-SVR
cohorts
SVR
n = 48
Non-SVR
n = 15
n (%) n (%)
Gender
Female 1 (2.1) 0
Male 47 (97.9) 15 (100)
Age (years)
Mean, standard
deviation
46, 8.23 41, 6.65
Median, range
(min, max)
46, 38 (29,67) 40, 28 (30,58)
Distribution (years)
25–34 3 (6.25) 2 (13.3)
35–44 15 (31.3) 11 (73.3)
45–54 24 (50) 1 (6.7)
55–64 5 (10.4) 1 (6.7)
>65 1 (2.1) 0
Race/Ethnicity
White 40 (83.3) 13 (86.7)
Black 2 (4.2) 0
Asian 5 (10.4) 1 (6.7)
Other 1 (2.1) 1 (6.7)
HCV Status
Acute 28 (58.3) 8 (53.3)
Chronic 20 (41.7) 7 (46.7)
HCV genotype*
Genotype 1 33 (68.8) 11 (73.3)
Genotype 2 2 (4.2) 0
Genotype 3 7 (14.6) 0
Genotype 4 6 (12.5) 4 (26.7)
HIV viral load† (copies/mL)
<50 36 (75) 13 (86.7)
≥50 12 (25) 2 (13.3)
CD4 count† (copies/lL)
101–500 19 (39.6) 3 (20)
501–1000 27 (56.3) 11 (73.3)
>1000 2 (4.2) 1 (6.7)
Median duration of
follow-up (years)
4 5
HCV, hepatitis C virus; HIV, human immunodeficiency
virus; SVR, sustained virological response. *Genotype for
which treatment given. †As of March 1st 2014.
© 2015 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
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treatment as opposed to only 25% (2/8) of genotype 2 and
22% (7/32) of genotype 3 patients (data not shown).
Twenty-five per cent (11/44) of patients treated for geno-
type 1 and (4/10) 40% of patients treated for genotype 4
failed therapy, whilst all individuals treated for genotypes 2
and 3 had successful outcomes.
Health service utilization post-treatment
Table 2 shows the annual healthcare utilization rates per-
patient for each of the services measured post-treatment.
The median duration of follow-up was 4 and 5 years for
SVR and non-SVR groups, respectively. Compared to those
with a SVR, non-SVR patients had higher annual utiliza-
tion rates for five of the nine measured healthcare services
(hospital admissions, fibroscans, USS, clinic visits and out-
patient attendances) in the 5 years following treatment.
A&E and night stays did not show a significant difference
between both cohorts, and this is due to the relatively low
utilization rates seen during each year of the follow-up.
We then investigated how the use of these services varied
between groups over the follow-up period. Figure 2 shows
the utilization rates per person year over the initial 5 years
upon treatment completion. Outpatient attendances were
significantly higher in non-SVR patients (3.3 visits per-
patient year) when compared to 1.5 for SVR patients
(P = 0.0022). Likewise, significant differences were seen in
the average number of clinic visits over the course of the
study with SVR and non-SVR using the service 1.1 and 2
times per-patient year, respectively (P = 0.0018). Those not
achieving SVR were more likely to have an ultrasound scan
and a fibroscan in the initial 5 years following treatment
with a relative risk (RR) of 14.93 (95% CI, 4.95–45.04,
P < 0.0001) and 10.40 (95% CI, 3.99–27.14, P < 0.0001),
Table 2 Annual post-treatment healthcare utilization of SVR vs non-SVR patients
Healthcare service
Years after treatment
Year 1* Year 2 Year 3 Year 4 Year 5
SVR Non-SVR SVR Non-SVR SVR Non-SVR SVR Non-SVR SVR Non-SVR
Outpatients attendances 1.81 4.20 1.77 3.07 1.3 3.29 1.23 2.31 1.3 2.44
Clinic visits 1.4 2.40 1.2 1.93 0.95 2.00 0.97 1.46 0.85 2.11
Hospital admissions 0.04 0.13 0.07 0.29 0.08 0.50 0.03 0.38 0 1
Nights stayed in hospital 0.02 0 0.02 0.21 0.05 0.29 0.1 0 0 0.11
A&E 0 0.7 0.07 0.07 0.08 0.07 0 0 0 0
Blood draws 2.48 2.93 2.2 2.21 1.9 2.43 1.6 1.54 1.65 2.11
HCV viral loads 1.19 1.47 1.09 0.86 0.98 1.07 0.67 0.54 0.45 0.56
USS 0 0.2 0.05 0.5 0 0.43 0 0.23 0.05 0.33
Fibroscans 0 0.2 0 0.29 0 0.36 0.1 0.31 0.05 0.33
HCV, hepatitis C virus; SVR, sustained virological response; USS, ultrasound scans. Rates for each year given per-patient.
*Beginning 12 weeks from treatment completion (SVR12).
Fig. 2 Frequency of healthcare
utilisation per patient-year. Total
follow-up years: 182 SVR, 65 non-SVR.
Statistical significance detected at
P < 0.05. HCV, hepatitis C virus; SVR,
sustained virological response; USS,
ultrasound scan; A&E, accident and
emergency.
© 2015 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
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respectively. There was an associated increase in relative
risk with the use of all listed healthcare services in the
absence of SVR; however, results for hospital admissions
and A&E visits did not prove statistically significant.
Resource costs post-treatment
To ascertain the financial benefits of attaining a SVR, we
calculated total costs for resource utilization. Table 3 shows
the estimated costs per service over the 5 year follow-up for
both cohorts. Patients who failed treatment incurred higher
healthcare utilization costs than those successfully treated,
and this trend is apparent in all measured services. Health-
care costs for non-SVR subjects totalled £2155 per-patient
year compared to only £1000 for SVR patients. Over a
5-year period, utilization costs would therefore amount to
£10 775 and £5000 for non-SVR and SVR patients, respec-
tively. As very few A&E visits were observed throughout
the study for both groups, the economic impact on reducing
admissions is small. The greatest disparities in costs
between the cohorts were found in ultrasounds amounting
to a 93% difference between groups.
DISCUSSION
The study found that within a HIV/HCV-co-infected popu-
lation with mild disease, unsuccessful treatment is associ-
ated with significantly higher costs (£1155 more per year)
of healthcare utilization per-patient following HCV therapy
than those who were successfully treated. Outpatient and
clinic attendances were higher in non-SVR patients when
compared to those achieving SVR (£766/£1000, 77%) in
comparison with non-SVR group (£1489/£2155, 69%). A
greater proportion of costs were attributable to hospital
admission in those who failed treatment. Of the minority of
patients who failed treatment, none had developed severe
fibrosis or cirrhosis throughout the duration of the study
and so healthcare analysis was not influenced by progres-
sion of disease. No significant difference was seen in the
number of bloods taken between both cohorts reflecting
the fact that both cohorts would continue to be monitored
for their HIV irrespective of treatment response. It is also
worth noting that although the total cost spent on inpa-
tient services (hospital admissions and night stays) was
higher for non-SVR patients (£471 per-patient) than SVR
patients (£91 per-patient), the rates for inpatient services
were very low for both groups (Table 2).
This study adds to the growing literature on the conse-
quences of successful treatment of HCV, which inform our
understanding of cost-effectiveness. This is the first study
to explore the impact of successful treatment in individuals
with HIV co-infection and mild disease, an important
group who may play a key role in ongoing transmission of
infection if not being prioritized for treatment based on
liver fibrosis. Recent work has explored the benefits of T
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treatment in HCV-monoinfected patients [17, 25], and a
different cohort from the one investigated here not least
because HCV-monoinfected individuals with mild disease
can potentially be discharged from secondary care after
successful treatment. A UK study reported a thirteen-fold
difference in costs between SVR and non-SVR patients with
chronic hepatitis C limited to those with genotype 1 [17].
The healthcare services measured in the study were similar
to those in our analysis with the addition of CT and MRI
scans in place of fibroscans. Total costs incurred for SVR
patients per year amounted to £54 in comparison with
£506 for those who failed treatment [17]. A US study cal-
culated post-treatment healthcare costs in monoinfected
HCV patients to be 1.6 times higher in non-SVR subjects
than those with successful outcomes upon treatment [25].
That study considered those with cirrhosis grouped along-
side patients with little or no liver disease and is thus not
directly comparable to our findings.
The study has several limitations. Outpatient atten-
dances, hospital admissions and A&E visits were recorded
based on all causes; we did not attempt to differentiate
whether utilization was due to liver related events caused
by HCV. Comorbidities such as obesity and diabetes were
not studied in detail and some change in use of services
may reflect non-hepatic consequences of infection. The
design of this study was intended to minimize the potential
for confounding in findings as a result of the lower SVR
rates seen in those with progressive fibrosis [20]. However,
we cannot exclude the fact that there may be patients
within the study where the extent of liver disease may be
underestimated by previous fibroscans and biopsies. Whilst
the largest study of this population to date, the numbers of
patients included are relatively small and the findings
require confirmation in other studies. In particular, data
from a larger number of centres would be helpful to estab-
lish if the data are representative of wider practice (for
example, the number of visits even in those patients
achieving SVR is greater than would be expected under
national guidelines). The SVR rates seen in this study are
relatively high (76%), and this likely reflects a significant
number of patients receiving treatment for acute infection.
Although different from the HCV mono-infection period,
this is quite typical of practice in co-infection.
Finally, the study relied on data from electronic data-
bases and patient records, and it may be that all patient-
related data were not captured (for example, attendances
at other centres or in primary care). It is not possible to
estimate the extent of this issue within this study although
it may lead to an underestimate of the changes in health
utilization. In addition, this study did not consider phar-
macy costs of HIV and other drugs received during the fol-
low-up period, which too will have contributed to the
overall healthcare costs for both cohorts.
The results from our study add to existing data inform-
ing the cost-effectiveness of antiviral therapies. Whilst we
cannot yet know whether successful DAA therapy will
have the same benefits, it is likely that the benefits will be
similar but further, ideally larger, studies are required. It is
possible that the difference between SVR and non-SVR
groups will change with a longer period of follow-up, but
it is likely that there will be greater divergence as disease
progression in the non-SVR group will require more fre-
quent monitoring.
In conclusion, this study was the first to compare the
impact of successful HCV treatment on healthcare utiliza-
tion in a HIV/HCV-co-infected population with mild dis-
ease. Our results show significant differences in healthcare
costs and utilization rates between individuals that are suc-
cessfully treated for HCV compared to those failing treat-
ment, despite the fact that they remain in secondary care.
The study provides data in addition to the known bene-
fits of SVR in reducing the risk of cirrhosis, hepatocellular
cancer, end-stage liver disease and disease transmission
[26] and adds to the evidence for cost-effectiveness of treat-
ment in this population.
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